31.39

2.82% 0.86

After Hours: 31.39

Ideaya Biosciences Inc (IDYA)

Overview News Price History Option Chain Financials Discussions Forecast

Ideaya Biosciences Inc stock is traded at $31.39, with a volume of 854.32K. It is up +2.82% in the last 24 hours and down -0.88% over the past month. IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

Previous Close:

$30.53

Open:

$30.89

24h Volume:

854.32K

Relative Volume:

0.93

Market Cap:

$2.76B

Revenue:

$218.71M

Net Income/Loss:

$-113.70M

P/E Ratio:

-24.08

EPS:

-1.3034

Net Cash Flow:

$-73.47M

1W Performance:

-5.76%

1M Performance:

-0.88%

6M Performance:

+22.19%

1Y Performance:

+74.29%

1-Day Range:

$30.84

$31.76

1-Week Range:

$29.57

$33.51

52-Week Range:

$13.45

$39.28

Ideaya Biosciences Inc Stock (IDYA) Company Profile

Name

Ideaya Biosciences Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

650-443-6209

Address

5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA

Employee

145

Twitter

Next Earnings Date

2026-02-13

Latest SEC Filings

IDYA's Discussions on Twitter

Compare IDYA vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IDYA Ideaya Biosciences Inc	31.39	2.68B	218.71M	-113.70M	-73.47M	-1.3034
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-07-26	Resumed	UBS	Buy
Nov-24-25	Initiated	Truist	Buy
Sep-18-25	Initiated	Guggenheim	Buy
Sep-04-25	Initiated	Barclays	Overweight
Sep-04-25	Initiated	Citizens JMP	Mkt Outperform
Jul-22-25	Initiated	TD Cowen	Buy
Jul-10-25	Resumed	Goldman	Neutral
Jun-26-25	Initiated	Wells Fargo	Overweight
Nov-18-24	Initiated	Stephens	Overweight
Nov-05-24	Downgrade	Leerink Partners	Outperform → Market Perform
Oct-24-24	Initiated	UBS	Buy
Oct-15-24	Initiated	Cantor Fitzgerald	Overweight
Jul-08-24	Initiated	Mizuho	Outperform
Mar-08-24	Initiated	BTIG Research	Buy
Aug-08-23	Initiated	SVB Securities	Outperform
May-24-23	Initiated	Goldman	Buy
Apr-24-23	Upgrade	Stifel	Hold → Buy
Mar-23-23	Initiated	Berenberg	Buy
Feb-28-23	Initiated	RBC Capital Mkts	Outperform
Dec-28-22	Initiated	CapitalOne	Overweight
Oct-27-22	Initiated	Citigroup	Buy
Aug-15-22	Downgrade	Stifel	Buy → Hold
Jul-18-22	Resumed	Oppenheimer	Outperform
Mar-10-22	Upgrade	Stifel	Hold → Buy
Sep-23-21	Initiated	Stifel	Hold
Jun-04-21	Resumed	Robert W. Baird	Outperform
Mar-11-21	Initiated	Guggenheim	Buy
Oct-07-20	Initiated	Wedbush	Outperform
Sep-01-20	Initiated	Northland Capital	Outperform
Jul-13-20	Upgrade	JP Morgan	Neutral → Overweight
Jun-17-20	Reiterated	H.C. Wainwright	Buy
Apr-06-20	Initiated	H.C. Wainwright	Buy
Mar-13-20	Initiated	ROTH Capital	Buy
Oct-17-19	Initiated	Oppenheimer	Outperform
Sep-10-19	Initiated	Robert W. Baird	Outperform
Jun-17-19	Initiated	Citigroup	Buy
Jun-17-19	Initiated	JP Morgan	Neutral
Jun-17-19	Initiated	Jefferies	Buy

View All

Ideaya Biosciences Inc Stock (IDYA) Latest News

Mar 23, 2026

RBC Capital reiterates Ideaya Biosciences stock rating on trial delay By Investing.com - Investing.com Canada

Mar 23, 2026

Jefferies reiterates Ideaya Biosciences stock rating on trial delay By Investing.com - Investing.com Canada

Mar 23, 2026

IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 6.1%Here's Why - MarketBeat

Mar 23, 2026

IDEAYA Biosciences Sees Unusually High Options Volume (NASDAQ:IDYA) - MarketBeat

Mar 23, 2026

Ideaya Biosciences stock maintained at Outperform by Mizuho on trial timing - Investing.com Canada

Mar 23, 2026

Citizens reiterates Ideaya Biosciences stock rating on mUM trial data By Investing.com - Investing.com Canada

Mar 23, 2026

Mar 22, 2026

IDEAYA delays darovasertib trial results to mid-April By Investing.com - Investing.com Canada

Mar 22, 2026

Cancer trial readout nears as IDEAYA targets first-half April lock - Stock Titan

Mar 22, 2026

Mar 21, 2026

IDEAYA Biosciences Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo

Mar 21, 2026

Mar 20, 2026

IDYA Stock Price, Quote & Chart | IDEAYA BIOSCIENCES INC (NASDAQ:IDYA) - ChartMill

Mar 20, 2026

Mar 19, 2026

(IDYA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Mar 19, 2026

Mar 18, 2026

Barclays Initiates Coverage of IDEAYA Biosciences (IDYA) with Overweight Recommendation - MSN

Mar 18, 2026

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and IDEAYA Biosciences (IDYA) - The Globe and Mail

Mar 18, 2026

IDEAYA Biosciences (IDYA) Gets a Buy from Mizuho Securities - The Globe and Mail

Mar 18, 2026

IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs - Barchart.com

Mar 18, 2026

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Mar 18, 2026

Mar 17, 2026